# A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

> **NCT02251288** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 62 (actual)

## Conditions studied

- Avian Influenza
- Immunisation

## Interventions

- **BIOLOGICAL:** Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca
- **BIOLOGICAL:** Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
- **DRUG:** MF59 adjuvant

## Key facts

- **NCT ID:** NCT02251288
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-18
- **Primary completion:** 2018-08-17
- **Final completion:** 2018-08-17
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251288, "A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02251288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*